Rachael Sood
Family · Mandeville, LANPI 1902181209
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Dexcom, Inc. at 38.3% of the total. 2025 is the largest year on record at $52,315, more than ten times the $619 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $256.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$28K
- Lilly USA, LLC$26K
- Sanofi-aventis U.S. LLC$10K
- Sequel Med Tech, LLC$3K
- Novo Nordisk$2K
- Medtronic$1K
- plus $2K from 14 others
What the payments were for
- Consulting fees$11,31516%
- Speaking & faculty fees$37,98652%
- Travel & lodging$16,81123%
- Food & beverage$6,7829%
- Education$200%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 87 | $27,927 |
| Lilly USA, LLC | 64 | $26,290 |
| Sanofi-aventis U.S. LLC | 41 | $9,901 |
| Sequel Med Tech, LLC | 2 | $3,217 |
| Novo Nordisk | 20 | $1,991 |
| Medtronic | 12 | $1,400 |
| BETA Bionics, Inc. | 7 | $441 |
| Abbott | 12 | $429 |
| AstraZeneca | 17 | $355 |
| Insulet Corporation | 5 | $229 |
| Cequr Corporation | 2 | $153 |
| Intra-sana Laboratories | 2 | $127 |
| Nevro Corp. | 3 | $118 |
| Mannkind Corporation | 4 | $117 |
| Tandem Diabetes Care, Inc. | 1 | $116 |
| Ascensia Diabetes Care US Inc. | 1 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 1 | $31 |
| Zealand Pharma US, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$26,042
- MOUNJARO$18,400
- DEXCOM STELO GLUCOSE BIOSENSOR$13,359
- TZIELD$5,815
- TWIIST$3,195
- RYBELSUS$1,590
- MINIMED 780G$1,165
- iLet Bionic Pancreas$1,010
- FreeStyle Libre$134
- FREESTYLE LIBRE 3$133
- SOLIQUA 100/33$122
- iLet Insulin Infusion Kit Inset$121
- iLet Insulin Infusion Kit Contact Detach$121
- DEXCOM G6 TRANSMITTER$120
- t:slim X2 Insulin Pump with Control-IQ$116
- Omnipod$102
- CeQur Simplicity$101
How this compares
$72,973 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 192 | $223,781 |
| OzempicSemaglutide | 159 | $194,238 |
| JardianceEmpagliflozin | 125 | $106,922 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 103 | $97,592 |
| TrulicityDulaglutide | 43 | $51,612 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $50,993 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 44 | $48,396 |
| FarxigaDapagliflozin Propanediol | 71 | $44,757 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $33,863 |
| RybelsusSemaglutide | 11 | $14,897 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $12,826 |
| NovologInsulin Aspart | 52 | $12,580 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,643 |
| HumalogInsulin Lispro | 53 | $11,249 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 16 | $11,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $26,290 | $287,727303 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,991 | $221,714222 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $9,901 | $97,592103 claims |
| AstraZenecaFarxiga | $355 | $44,75771 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Mandeville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.